A high-quality pharmaceutical business with a wide economic moat, 37% margins, and four consecutive earnings beats averaging 27.5% upside surprise is a compelling long-term franchise, but the share price now trades above the analyst consensus target, estimates have fallen 17.2% over 30 days, and the risk/reward is deeply unfavorable—this is a hold for existing positions, not an entry.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business maintains a wide economic moat, 37% operating margins ranking best-in-class among peers, and a Piotroski F-Score of 8 out of 9—indicators of a durable competitive position generating returns well above the cost of capital across business cycles. Quality breakdown | Operating margins remain at or above 35% over the next 12 months, confirming that the moat is protecting the franchise from competitive erosion. | →Stable |
| CounterFree cash flow converts at 78% of reported net income—a quality flag—suggesting a gap between accounting earnings and actual cash generation; if this gap widens, reported margins may overstate the true cash economics of the business. | ||
Four consecutive quarters of earnings beats with an average EPS surprise of 27.5% reflects a pattern of consistently delivering results well above sell-side expectations—a track record that typically underpins sustained price appreciation over time. Catalyst track record | The beat streak extends beyond 6 consecutive quarters, with average EPS surprise remaining above 15%, sustaining the pattern of consistent outperformance. | →Stable |
| CounterAnalyst estimates have fallen 17.2% over the past 30 days, suggesting the sell side is resetting its models downward; if estimates are marked down sufficiently, future beats become mechanically easier without reflecting genuine business improvement, and the beat streak may not translate to price appreciation if it comes against a materially lower bar. | ||
At 31.37, the share price trades approximately 2% above the analyst consensus target of 30.76, producing a negative reward-to-risk profile; the asymmetry is deeply unfavorable, with a downside risk of roughly 15% and no meaningful upside to the analyst consensus at current levels. Price targets | Analyst consensus target rises above 36.00, creating more than 14% upside from the current price of 31.37 and converting the reward/risk to favorable for a new entry. | →Stable |
| CounterA four-for-four beat streak with wide moat characteristics may prompt upward analyst target revisions; if earnings continue outperforming by 20%-plus and targets are revised higher, the current premium to consensus could quickly look modest in retrospect. | ||
The business maintains a wide economic moat, 37% operating margins ranking best-in-class among peers, and a Piotroski F-Score of 8 out of 9—indicators of a durable competitive position generating returns well above the cost of capital across business cycles.
→Stable- Expectation
- Operating margins remain at or above 35% over the next 12 months, confirming that the moat is protecting the franchise from competitive erosion.
CounterFree cash flow converts at 78% of reported net income—a quality flag—suggesting a gap between accounting earnings and actual cash generation; if this gap widens, reported margins may overstate the true cash economics of the business.
Four consecutive quarters of earnings beats with an average EPS surprise of 27.5% reflects a pattern of consistently delivering results well above sell-side expectations—a track record that typically underpins sustained price appreciation over time.
→Stable- Expectation
- The beat streak extends beyond 6 consecutive quarters, with average EPS surprise remaining above 15%, sustaining the pattern of consistent outperformance.
CounterAnalyst estimates have fallen 17.2% over the past 30 days, suggesting the sell side is resetting its models downward; if estimates are marked down sufficiently, future beats become mechanically easier without reflecting genuine business improvement, and the beat streak may not translate to price appreciation if it comes against a materially lower bar.
At 31.37, the share price trades approximately 2% above the analyst consensus target of 30.76, producing a negative reward-to-risk profile; the asymmetry is deeply unfavorable, with a downside risk of roughly 15% and no meaningful upside to the analyst consensus at current levels.
→Stable- Expectation
- Analyst consensus target rises above 36.00, creating more than 14% upside from the current price of 31.37 and converting the reward/risk to favorable for a new entry.
CounterA four-for-four beat streak with wide moat characteristics may prompt upward analyst target revisions; if earnings continue outperforming by 20%-plus and targets are revised higher, the current premium to consensus could quickly look modest in retrospect.
▸ Show 1 more pillar▾ Show fewer
Two high-severity supplier concentration risks create tail risk for a business that has otherwise demonstrated exceptional earnings consistency; if either supply relationship is disrupted, the earnings trajectory that underpins the premium valuation could reverse sharply.
→Stable- Expectation
- The beat streak extends beyond 8 consecutive quarters without a supply-disruption miss, demonstrating that the supplier relationships are operationally stable and the tail risk has not materialized at current business scale.
CounterThe elevated put/call ratio of 16.69 may already be pricing in this tail risk; if no disruption materializes over the next several quarters, the bearish options overhang could unwind sharply and provide an additional price catalyst beyond the earnings beat dynamics.
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis
Temp Headwind edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $31.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Santhera; Concentration risk — Supplier: Eisai.
Catalyst Pharmaceuticals sells three FDA-approved rare-disease drugs in the U.S.: FIRDAPSE® for Lambert-Eaton Myasthenic Syndrome (approved 2018), AGAMREE® for Duchenne muscular dystrophy (approved Oct 2023, launched March 2024), and FYCOMPA® for epilepsy (generics entered;... Read more
Hold if already holding. Not a fresh buy at $31.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Santhera; Concentration risk — Supplier: Eisai. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 42d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
About Catalyst Pharmaceuticals, Inc.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals' commercial portfolio spans three FDA-approved rare-disease drugs: FIRDAPSE (amifampridine) for Lambert-Eaton Myasthenic Syndrome, approved November 2018; AGAMREE (vamorolone) for Duchenne muscular dystrophy, approved October 2023 and launched March 2024; and FYCOMPA (perampanel) for epilepsy, acquired from Eisai in January 2023. AGAMREE net product revenues exceeded $100 million in 2025. Catalyst held about $709 million in cash at December 31, 2025, with all commercial sales conducted in the U.S.
Catalyst earns revenue from prescriptions dispensed through a small group of exclusive specialty pharmacies, primarily AnovoRx, with high per-patient prices required to generate meaningful gross margins given very small patient populations—DMD affects an estimated 11,000 to 13,000 people in the U.S., with approximately 70% currently receiving corticosteroid treatment. FIRDAPSE is marketed by roughly 23 field personnel under the Catalyst Pathways patient support program; AGAMREE has a dedicated field force of roughly 16 sales representatives since April 2025, following separation of the two commercial teams on April 1, 2025. FYCOMPA lost its primary patent in May 2025 and now faces three approved generic tablet competitors; Catalyst ceased active FYCOMPA marketing on December 31, 2025. AGAMREE is currently supplied by Santhera Pharmaceuticals under the AGAMREE License Agreement, with transition to a U.S. manufacturing site planned for completion by end of 2026; FYCOMPA is manufactured by Eisai under a Supply Agreement through at least end of 2029.
Show full overview
FIRDAPSE patent protection extends through 2032, with key Orange Book patents running to 2034 and 2037. Of three ANDA challengers, Teva settled in January 2025 and Lupin in August 2025, each agreeing to no generic FIRDAPSE market entry before February 25, 2035. The third challenger, Hetero, remains in active litigation in the U.S. District Court for the District of New Jersey, with trial scheduled for March 23, 2026—before the statutory 30-month ANDA stay expires in May 2026. If Hetero prevails, it could gain market entry ahead of the 2035 dates agreed with Teva and Lupin, materially affecting FIRDAPSE revenues before the 2032–2037 patent expiration window.
See also: Healthcare · Biotechnology
From Catalyst Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-24Recent Developments — Catalyst Pharmaceuticals, Inc.
Latest news
- NEWS Catalyst (CPRX) Stalls at $31.25 — Consolidation Phase 2026-05-20 - Money Flow Index - Newser — Newser neutral
- NEWS Catalyst (CPRX) Stalls at $31.25 — Consolidation Phase 2026-05-20 - Trending Volume Leaders - Newser — Newser neutral
- NEWS Catalyst (CPRX) Stalls at $31.25 — Consolidation Phase 2026-05-20 - Professional Trade Ideas - Newser — Newser neutral
- NEWS Catalyst (CPRX) Stalls at $31.25 — Consolidation Phase 2026-05-20 - ETF Flow - Newser — Newser neutral
- NEWS Catalyst (CPRX) Stalls at $31.25 — Consolidation Phase 2026-05-20 - ETF Flow - newser.com — newser.com neutral
Generated 2026-06-25T01:32:42Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierSanthera10-K Item 1: 'we agreed to purchase commercial supply of AGAMREE® from Santhera at agreed upon prices until we completed our process to transition to our own direct supplier'
- HIGHSupplierEisai10-K Item 1A: 'also purchase FYCOMPA® supplies from Eisai through at least the end of 2029'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Negative sentiment — recent news tone and/or analyst downgrades drag the composite below neutral.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $31.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Santhera; Concentration risk — Supplier: Eisai. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $30.80 (-1.9%), stop $31.34 (−0.2%), A.R:R -1.0:1. Score 5.6/10, moderate confidence.
Take-profit target: $30.80 (-2.0% upside). Target $30.80 (-1.9%), stop $31.34 (−0.2%), A.R:R -1.0:1. Stop-loss: $31.34.
Concentration risk — Supplier: Santhera; Concentration risk — Supplier: Eisai; Analyst target reached - limited upside remaining.
Catalyst Pharmaceuticals, Inc. trades at a P/E of 18.2 (forward 9.9). TrendMatrix value score: 6.5/10. Verdict: Hold.
12 analysts cover CPRX with a consensus score of 3.7/5. Average price target: $32.
What does Catalyst Pharmaceuticals, Inc. do?Catalyst Pharmaceuticals sells three FDA-approved rare-disease drugs in the U.S.: FIRDAPSE® for Lambert-Eaton...
Catalyst Pharmaceuticals sells three FDA-approved rare-disease drugs in the U.S.: FIRDAPSE® for Lambert-Eaton Myasthenic Syndrome (approved 2018), AGAMREE® for Duchenne muscular dystrophy (approved Oct 2023, launched March 2024), and FYCOMPA® for epilepsy (generics entered; active marketing ceased December 2025). The company held roughly $709 million in cash at year-end 2025.